Among a group of patients receiving re-irradiation for recurrent high-grade glioma, overall survival from time of recurrence was similar among patients younger than 65 and those aged 65 or older, according to data out of the ASTRO Annual Meeting.1
In a single-center, retrospective study, researchers looked at outcomes among 118 patients with recurrent high-grade glioma treated with re-irradiation between January 2013 and July 2019; 22% of patients were 65 years or older. The majority (90%) of patients were treated with concurrent temozolomide; 78% were treated with adjuvant temozolomide after initial radiation.
Older patients did have worse overall survival at 5 years compared with younger patients (7.2% vs 25.1%), but overall survival was not significantly different between the groups from time of recurrence (P =.177).
Continue Reading
IDH or MGMT status, extent of surgical resection, type of systemic therapy at recurrence, or tumor location did not predict for overall survival. Additionally, there was no difference in overall survival observed in patients who received a bevacizumab-containing regimen compared with those who did not.
Only 2 patients had grade 3 or higher toxicities.
According to the researchers, these results indicate a role for re-irradiation in the elderly population.
Reference
Ali A, Song A, Zhan T, et al. Elderly patients with recurrent high grade glioma derive similar benefit from re-irradiation as younger patients. Presented at ASTRO Annual Meeting;October 24-27, 2020. Poster 3717.
